Iprabronch (Ipratropium Bromide)

Ipratropium bromide acts as a competitive antagonist at muscarinic (M1 and M3) acetylcholine receptors located on airway smooth muscle and sub‑mucosal glands. By blocking acetylcholine binding, it prevents bronchoconstriction and decreases secretions, resulting in bronchodilation and clearer airways.

The specific dose and frequency of Iprabronch are determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Healthcare professionals select the appropriate inhalation regimen and device according to approved labeling and individual therapeutic needs.

Safety data for ipratropium bromide in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Iprabronch, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Iprabronch (ipratropium bromide) belongs to the anticholinergic class, whereas many alternatives such as albuterol are β2‑agonists. Anticholinergics provide longer‑lasting bronchodilation with a lower risk of tachycardia, but may cause dry mouth. In practice, ipratropium is often combined with β2‑agonists for additive effect, especially in moderate‑to‑severe COPD.

Iprabronch should be stored at room temperature, below 25 °C, in its original container to protect it from moisture, heat and light. The inhalation device should be kept clean, and any unused portion should be discarded according to local regulations after the indicated expiry date.

Iprabronch is delivered via inhalation using a metered‑dose inhaler or nebulizer, as specified on the product label. The patient inhales the prescribed number of puffs or nebulized dose, typically holding the breath for a few seconds to allow optimal drug deposition in the lower airways. Proper technique should be taught by a healthcare professional.

Although uncommon, serious adverse reactions can include paradoxical bronchospasm, severe allergic responses such as angio‑edema or anaphylaxis, and urinary retention or glaucoma exacerbation in susceptible individuals. Any sudden worsening of breathing, rash, swelling of the face or throat, or difficulty urinating should prompt immediate medical evaluation.

Iprabronch is contraindicated in patients with known hypersensitivity to ipratropium bromide or any of the inhaler excipients. Caution is advised in individuals with narrow‑angle glaucoma, urinary retention, or severe obstructive uropathy, as anticholinergic effects may worsen these conditions. A healthcare professional should assess suitability before initiating therapy.